Retrospective Cohort Study
Copyright ©The Author(s) 2015.
World J Gastroenterol. Jun 28, 2015; 21(24): 7488-7494
Published online Jun 28, 2015. doi: 10.3748/wjg.v21.i24.7488
Table 1 Univariate analysis of risk factors related to spontaneous rupture of hepatocellular carcinoma
VariablesPatients (n = 79)P value
Age (yr)55.8 ± 12.6< 0.001
Lesion length (cm)7.7 ± 3.5< 0.001
Number (1/2-3/≥ 5)39/10/30< 0.001
Location (left lobe/right lobe)34/450.934
Cirrhosis (absence/presence)30/49< 0.001
Virus (None/HBV/HCV)20/57/20.150
BCLC stage (A/B/C)10/47/22< 0.001
Treatment before rupture (absence/presence)53/26< 0.001
Treatment at rupture (conservative/TAE/surgery)30/32/170.086
Treatment in the follow-up period (absence/presence)60/19< 0.001
WBC, × 109/L12.4 ± 5.4< 0.001
HB, g/L106.2 ± 25.6< 0.001
PLT, × 1010/L171 ± 84.4< 0.001
INR1.3 ± 0.3< 0.001
APTT, S38.4 ± 7.2< 0.001
ALT, U/L127 ± 186.9< 0.001
ALB, g/L30.8 ± 7.3< 0.001
TBil, umol/L28.3 ± 20.9< 0.001
HCO3-, mmol/L23.3 ± 5.6< 0.001
Crea, umol/L95.7 ± 50.1< 0.001
Child-Pugh7.9 ± 1.8< 0.001
Table 2 Multivariate analysis of risk factors related to survival in patients with hepatocellular carcinoma rupture
VariablesHR95%CIP value
Age (yr)0.960.93-1.000.026
Lesion length (cm)1.461.23-1.73< 0.001
Number1.371.01-1.850.042
Cirrhosis (presence)2.470.77-7.960.131
BCLC stage A (control)---
BCLC stage B0.100.02-0.410.002
BCLC stage C0.190.03-1.010.052
Treatment before rupture (presence)4.361.27-14.990.019
Treatment in follow-up period (presence)0.210.07-0.670.008
WBC, × 109/L1.040.96-1.130.375
HB, g/L0.990.97-1.000.314
PLT, × 1010/L1.000.99-1.000.143
INR0.390.04-3.600.406
APTT, S1.070.99-1.150.103
ALT, U/L1.001.00-1.010.011
ALB, g/L0.890.81-0.970.010
TBil, umol/L1.000.97-1.020.735
HCO3-, mmol/L1.181.08-1.28< 0.001
Crea, umol/L1.011.00-1.020.089
Child-Pugh1.030.59-1.800.905